Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.

Recs

0

Here's Why Innoviva Inc. Lost 10% Today

What happened

Shares of Innoviva (NASDAQ: INVA  ) , a biotechnology royalty company that develops respiratory therapeutics and is perhaps best known as GlaxoSmithKline's (NYSE: GSK  ) development partner for its multiple next-generation COPD and asthma products, fell as much as 11% on Thursday. The reason behind Innoviva's bad day can be traced to a proxy battle with activist hedge fund Sarissa Capital Management over seats on its board.

So what

According to a press release from Sarissa Capital on Wednesday evening (since Innoviva has thus far declined to comment), Innoviva had agreed to settle its proxy fight by allowing Sarissa two board seats. However, according to reports, Innoviva continued to lobby for votes from shareholders without disclosing the fact that a deal had been reached with Sarissa Capital. Sarissa sent over the signed paperwork to Innoviva on Wednesday afternoon agreeing to the settlement but was told by Innoviva that it would renege on its offer to place two of Sarissa's choices on its board. When the smoke cleared, Innoviva had narrowly garnered enough votes to keep its own members on the board.

A lab researcher using multiple pipettes.

Image source: Getty Images.

Sarissa Capital Management, which owns 2.72% of Innoviva's outstanding shares, has been critical of the company's executive compensation. As GlaxoSmithKline's partner for Breo Ellipta, Anoro Ellipta, Incruse, and Arnuity, Innoviva has the sole task of managing the royalties it receives from Glaxo. Sarissa alleges that high executive-compensation levels are reducing its profitability and hampering returns for shareholders. Thus, Sarissa's failure to get any board seats is being construed as bad news for shareholders that any meaningful cost-cutting will happen in the near future.

For what it's worth, GlaxoSmithKline, which has a 29.3% stake in Innoviva, opposed Sarissa's attempts to get their members on Innoviva's board.

Now what

While today's made-for-TV drama caused Innoviva's stock to tumble 10%, and shareholders are clearly not pleased with having an activist investor lose out on board seats, this probably isn't a long-term issue for the company. Innoviva has pledged to take a closer look at its executive compensation, and with the matter now in the public light, it's unlikely that it'll be swept under the rug.

What's far more important for Innoviva shareholders at this point is the continued growth of it and Glaxo's respiratory products. Though these next-generation products offer new, long-lasting solutions to patients, infiltrating the market is taking more time than expected. Physicians and consumers have been using mature and effective therapies for years, and educating them that new choices are available is a tedious process. It also has taken time for GlaxoSmithKline to gain adequate insurer coverage on its new therapies.

Patient investors will probably be well rewarded, with Wall Street projecting $2.33 in full-year EPS by 2019, but we'll also need to see Innoviva making a serious effort to cut costs and pay down its existing debt. 

10 stocks we like better than Innoviva Common Stock
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Innoviva Common Stock wasn't one of them! That's right -- they think these 10 stocks are even better buys.

Click here to learn about these picks!

*Stock Advisor returns as of April 3, 2017


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 4014624, ~/Articles/ArticleHandler.aspx, 4/27/2017 2:46:15 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
Change up DOW 20989.8 14.7 0.1%
Change up S&P 500 2390.2 2.8 0.1%
Change up NASD 6045.0 19.8 0.3%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

4/27/2017 2:30 PM
INVA $12.62 Down -0.23 -1.79%
Innoviva Common St… CAPS Rating: ****
GSK $40.85 Up +0.17 +0.42%
GlaxoSmithKline CAPS Rating: ***

Advertisement